Recent developments in health and medicine include new ADHD treatment approvals, findings on pediatric care, and public health concerns regarding nutrition and occupational safety.
Key Points
The FDA has granted approval for Simtriyo (centanafadine), marking the first norepinephrine, dopamine, and serotonin reuptake inhibitor for the treatment of ADHD in both adults and children.
A randomized trial indicates that children participating in weight management programs show greater reductions in body mass index when a family-based component is included.
A new analysis of a pediatric vitiligo registry is providing clinical insights that may help establish updated practice standards for treating the skin condition in children.
Former FDA Commissioner Scott Gottlieb warned of potential widespread Cyclosporiasis contamination in produce sourced from Central Mexico, prompting some retailers to halt supply.
Research reveals that over 60% of American adults desire weight loss, with those individuals being significantly more prone to unhealthy habits like meal skipping and purging.
The GMC's 2026 National Training Survey highlights a concerning rise in reports of unwelcome sexual conduct among trainee doctors, alongside ongoing issues with burnout and workplace pressure.
New studies emphasize the link between obesity and cognitive decline, identifying several underlying physiological factors that connect the two health conditions.
A clinical study reports that Pyoderma Gangrenosum, a condition characterized by painful ulcers, demonstrates a high likelihood of recurrence even after complete healing is achieved.